HYCOR Biomedical Announces Issuance of Key Patent on Disruptive Platform for Allergy and Autoimmune Testing
GARDEN GROVE, California, Sept. 22, 2015 /PRNewswire/ -- HYCOR Biomedical, a leading manufacturer of in vitro diagnostic products for allergy and autoimmune testing, announced today that the company has been awarded the first key patent on its new immunochemistry analyzer. The patent, US patent #9,075,055, protects the novel optics apparatus designed as part of the system. This is the first of nine key patents related to the platform for which HYCOR has applied.
"Initiating development in 2011, our team has made tremendous progress with the system now entering verification and validation. We are excited about the emerging patent estate as we move toward regulatory approvals," said Richard Aderman, President and CEO of HYCOR.
Vice President of R&D, Dr. Mark Van Cleve, commented, "We set out to provide the customer with a cutting-edge immunoassay platform incorporating universal microbeads. However, our application of the technology required optics capabilities that did not exist in the market. HYCOR responded by designing a proprietary optics apparatus combining two proven analyzer technologies: chemiluminescence and fluorescence. The novelty of this combination is captured in the first issued patent."
Dr. Van Cleve further commented "Leveraging the universal microbead foundation, we have designed a system with multiple other disruptive features, which are captured in additional key patent filings. We look forward to introducing these game-changing enhancements as we continue to roll out our platform, the first major innovation in the global allergy diagnostic market of the 21st century."
"HYCOR's approach to immunochemistry for allergy and autoimmune testing is the most novel we have reviewed in over 25 years of working in this space," said Louis Cullman of patent firm K&L Gates.
About Allergy and Autoimmune
Allergic diseases, including asthma, are the 5th most common chronic disease in the U.S. for all ages, and the 3rd most common chronic disease in children. Allergy is one of the fastest growing testing disciplines in the clinical laboratory market throughout the world. Over 50 million Americans and more than 150 million Europeans suffer from allergies. Nearly 24 million Americans and 30 million Europeans suffer from autoimmune diseases.
About HYCOR Biomedical
Founded in 1981, HYCOR is a global manufacturer and marketer of in vitro diagnostics products. Among its products, HYCOR markets the HYTEC™ and AUTOSTAT™ brands. The company is focused on delivering products that provide the highest value to clinicians through innovation, reliability and customer service. For more information, please visit www.hycorbiomedical.com.
This press release contains certain forward-looking statements that include projections and may also include words such as may, will, expects, believes, anticipates, plans, estimates, seeks, could, intends, and other similar expressions. These forward-looking statements involve risks, uncertainties, assumptions and other factors that are difficult to predict and that could cause actual results to vary materially from what is expressed in or indicated by the forward-looking statements.
Share this article